<DOC>
	<DOCNO>NCT02074631</DOCNO>
	<brief_summary>This Phase 2 , open-label , randomize , control clinical study pediatric subject treat pamidronate calcium vitamin D versus calcium vitamin D alone follow hematopoietic cell transplantation ( HCT ) . The purpose study test hypothesis subject receive pamidronate calcium vitamin D high lumbar spine bone mineral content ( LBMC ) measure dual-energy X-ray tomography ( DXA ) 1 year post-HCT subject receive calcium vitamin D alone ( Control Group ) .</brief_summary>
	<brief_title>Prevention Bone Loss After Pediatric Hematopoietic Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>Allogeneic hematopoietic cell transplant hematologic malignancy ( i.e . leukemia , lymphoma include ALL , AML , CML , NHL , HL ) complete remission ; myelodysplastic syndrome ( active dysplasia and/or blast permit , must active leukemia ) idiopathic severe aplastic anemia ( SAA ) Myeloablative preparative regimen ( SAA condition therapy allow ) Male female ≥1 ≤ 20 year age time study enrollment Patient parent ( ) /legal guardian ( ) able willing provide inform consent . Assent obtain per local institutional policy . Subjects turn 18 course study consent time next visit member research staff . History primary bone malignancy involve lumbar spine Prior and/or plan concomitant medical therapy study period ( Day 360 postHCT ) bisphosphonates , Denosumab , Teriparatide Pregnancy breastfeed menstruate female must negative pregnancy test prior study enrollment agree repeat pregnancy test contraception use per protocol pamidronate Pregnancy Category D positive evidence human fetal risk base adverse reaction data Renal insufficiency , define creatinine level great upper limit normal age Hereditary metabolic bone disease skeletal dysplasia ( e.g. , osteopetrosis OI ) primary hyperparathyroidism Other indication HCT , include Fanconi anemia , form inherit bone marrow failure diseases , metabolic disorder , hemoglobinopathy , immune deficiency Clinically significant fracture define ISCD ( long bone fracture low extremity , vertebral compression fracture , two long bone fracture upper extremity ) ( 88,89 ) indicate cast spine xray within last 2 week Known suspected allergy pamidronate relate product Planned administration investigational study drug agent either interact pamidronate independent effect bone mineral density within 4 week prior randomization ( Day 90 ) plan use study participation ( Day 90 Day 360 ) Impending invasive dental procedure would expect occur study participation ( Day 360 )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>bone mineral content</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>bone formation</keyword>
	<keyword>bone resorption</keyword>
	<keyword>pamidronate</keyword>
	<keyword>child</keyword>
	<keyword>DXA</keyword>
	<keyword>bone marrow transplant</keyword>
</DOC>